Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase(R) Lists Warrants on the TSXV
07:00am, Wednesday, 03'rd Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage
Theralase(R) Releases Q1 2026 Financial Statements
05:03pm, Friday, 29'th May 2026
Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase
Theralase(R) Closes C$4.8 Million Offering
11:06am, Wednesday, 20'th May 2026
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to th
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
02:50pm, Tuesday, 12'th May 2026
Theralase Technologies Inc. (TLT:CA) Q4 2025 Earnings Call Transcript
Theralase(R) Announces $4 Million Brokered LIFE Offering
07:10pm, Tuesday, 05'th May 2026
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TL
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
05:22pm, Monday, 04'th May 2026
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study
07:00am, Monday, 13'th Apr 2026
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to
Theralase(R) Closes $CAN 2.66 Million Financing
07:00am, Friday, 10'th Apr 2026
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to
Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus
07:00am, Tuesday, 17'th Mar 2026
Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
07:00am, Monday, 02'nd Mar 2026
Toronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a
This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Techn
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
07:00am, Tuesday, 17'th Feb 2026
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
07:00am, Tuesday, 10'th Feb 2026
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated
Theralase(R) Provides Update on Bladder Cancer Clinical Study
07:00am, Wednesday, 04'th Feb 2026
Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario--(Newsfile Corp. - Febr
